{"filings":[{"id":9,"accession_number":"0001140361-26-020407","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2026-05-11T13:30:08+00:00","items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"status":"ready","headline":"Kezar Life Sciences acquired by Aurinia for $6.955/sh + CVR; stock to be delisted","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer expired May 8, 2026; 5,927,580 shares (80.2% of outstanding) validly tendered.","Merger completed May 11, 2026 under DGCL Section 251(h); Kezar became wholly owned subsidiary of Aurinia.","Consideration: $6.955 per share in cash plus one contingent value right per share (CVR Agreement filed as Exhibit 10.1).","Entire board (7 directors) resigned; Kevin Tang and others from Merger Sub became directors and officers of surviving corporation.","Shares will be suspended and delisted from Nasdaq; company intends to file Form 15 to terminate registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94357,"accession_number":"0001628280-26-023703","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.02","5.02","9.01"],"status":"ready","headline":"Kezar Life Sciences terminates HQ lease, separates CEO, CFO, and COO ahead of Aurinia merger","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lease for ~48,714 sq ft at 4000 Shoreline Court terminated April 1; company pays $2M ( $1.3M cash + $0.7M security deposit).","CEO Christopher Kirk, CFO Marc Belsky, and COO Mark Schiller enter separation agreements; employment ends at merger close or earlier.","Kirk receives lump-sum severance of 18 months base salary plus pro-rata bonus; Belsky and Schiller get 12 months COBRA cash payment.","No disagreements between officers and company; severance contingent on signing general release.","Merger with Aurinia Pharma U.S. at $6.955/share plus CVR still expected to close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106645,"accession_number":"0001193125-26-130486","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Kezar Life Sciences to be acquired by Aurinia Pharma for $6.955 per share cash plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aurinia Pharma U.S. will commence a tender offer at $6.955/share cash plus one contingent value right (CVR) per share.","Tang Capital Partners, holding ~9% of shares, agrees to tender in support of the deal.","CVR holders may receive payments from excess net cash above $50M, Enodia APA proceeds, and milestones/royalties from zetomipzomib.","Closing expected in Q2 2026; conditions include minimum tender >50% and net cash ≥$50M.","Termination fee of $1.2 million payable by Kezar under specified circumstances, including a superior proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106644,"accession_number":"0001628280-26-017046","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","2.01","7.01","2.02","9.01"],"status":"ready","headline":"Kezar sells Sec61 assets (incl. KZR-261) to Enodia for $1M upfront, up to $127M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Kezar receives $1M cash upfront ($800K at close, $200K later) for its Sec61-based discovery program and KZR-261.","Eligible for up to $127M in development, regulatory and commercial milestone payments plus tiered royalties on net sales.","Kezar retains its zetomizomib program; no other assets (cash, equipment, employee contracts) transferred.","Transaction closed March 6, 2026; joint press release issued March 12, 2026.","Agreement includes indemnification caps of $1M per party (excluding fraud) and customary covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122977,"accession_number":"0001628280-25-051592","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar fails to align with FDA on zetomipzomib trial; cuts workforce 70%, begins strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unable to align with FDA on registrational trial for zetomipzomib in autoimmune hepatitis; strategic review with TD Cowen initiated.","Workforce reduced by ~31 employees (70%); expects ~$6.0M in severance costs in Q4 2025.","Repaid $6.3M to Oxford Finance in full; cash and marketable securities $90.2M at September 30, 2025.","Net loss Q3 2025: $11.2M ($1.53/share) vs $20.3M ($2.78) in Q3 2024; R&D down to $6.9M from $16.2M.","Retained essential employees for value creation; 7.3M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122976,"accession_number":"0001628280-25-050671","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Kezar Life Sciences cuts 70% of workforce (~31 employees) as part of strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~31 employees (approx. 70% of total staff) announced on Nov 6, 2025.","Estimated cash expenditures of ~$6.0M for severance and benefits, majority recognized in Q4 2025.","Restructuring linked to previously announced evaluation of strategic alternatives for the company.","Company may incur additional costs; will amend filing if material changes arise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122975,"accession_number":"0001628280-25-045871","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Kezar Life Sciences repays $6.3M in full, terminates Loan Agreement with Oxford Finance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $6.3M in full satisfaction of outstanding amount including accrued interest and exit fees.","Loan and Security Agreement dated Nov 4, 2021 terminated; all liens and security interests released.","Repayment made using cash on hand; no new debt incurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122974,"accession_number":"0001628280-25-045215","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","3.03","2.02","8.01","9.01"],"status":"ready","headline":"Kezar Life Sciences ends AIH program after FDA setback, begins strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cancelled Type C meeting for zetomipzomib in autoimmune hepatitis; requires PK study causing ~2-year delay and 48-hour in-unit monitoring.","Company to explore strategic alternatives, retain TD Cowen; restructuring includes workforce reduction and cost containment.","Preliminary cash, equivalents and marketable securities of $90.2M as of Sep 30, 2025 (unaudited).","Rights plan amended to extend expiration to after 2026 annual meeting (or 2027 if ratified); not in response to takeover threat.","PORTOLA final data still to be presented at The Liver Meeting Nov 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139680,"accession_number":"0001645666-25-000036","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Life Sciences Q2 net loss $13.7M; FDA lifts partial hold on AIH trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.7M ($1.87/share) vs $21.5M loss in Q2 2024; R&D expenses down 41% to $9.6M.","Cash, equivalents & marketable securities $100.8M as of June 30, 2025 ($132.2M at Dec 31, 2024).","FDA removed partial clinical hold on PORTOLA Phase 2a trial for zetomipzomib in autoimmune hepatitis.","Submitted Type C meeting request to FDA for Q4 2025 to discuss registration-enabling AIH study design.","PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting 2025 (Nov 7-11)."],"consensus_eps_estimate":-2.4126,"consensus_eps_actual":-4.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157256,"accession_number":"0001645666-25-000029","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kezar shareholders elect directors, approve say-on-pay, ratify KPMG; two directors face majority withhold","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elizabeth Garner elected as Class I director with 2,148,505 votes for; Michael Kauffman and Courtney Wallace also elected despite more withheld votes than for.","Advisory vote on executive compensation approved with 2,151,745 for (54.7%), 1,781,942 against, 7,980 abstain; broker non-votes 2,240,480.","Ratification of KPMG as auditor for 2025 passed with 6,116,820 for, 56,801 against, 8,526 abstain.","High withhold votes for Kauffman (2,322,932 withheld vs 1,618,735 for) and Wallace (2,390,314 withheld vs 1,551,353 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157255,"accession_number":"0001645666-25-000026","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"KZR Q1 2025 net loss $16.6M; positive PORTOLA data in AIH","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $114.4M at March 31, 2025, down from $132.2M at Dec 31, 2024.","Net loss $16.6M ($2.27/share) vs $21.7M ($2.98) in Q1 2024.","PORTOLA Phase 2a: 36% zetomipzomib patients achieved CR with steroid taper vs 0% placebo in relapsed AIH.","R&D expenses fell $5.0M to $12.2M due to PALIZADE trial termination.","Responding to FDA partial clinical hold on PORTOLA; no flares in CR patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157254,"accession_number":"0001645666-25-000014","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kezar Life Sciences appoints Pichi Chiang as principal accounting officer, effective April 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pichi Chiang, age 63, appointed principal accounting officer, effective April 1, 2025.","Chiang previously served as SVP Corporate Controller since May 2018; no new compensatory arrangements.","Marc Belsky remains CFO and principal financial officer; Chiang assumes accounting officer role from Belsky."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175625,"accession_number":"0001645666-25-000009","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Kezar Life Sciences: positive PORTOLA Phase 2a data; steroid-sparing remissions in AIH, cash $132M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["31% of zetomipzomib patients achieved CR + steroid taper ≤5 mg/day vs 12.5% placebo in ITT (n=24).","In steroid-dependent subgroup, 36% zetomipzomib CR + taper ≤5 mg/day vs 0% placebo; median response 27.6 weeks.","No Grade 4/5 AEs; injection site reactions most common; one placebo SAE (variceal bleed), two zetomipzomib SAEs (fever, flu).","FY2024 net loss $83.7M vs $101.9M in 2023; cash $132.2M at Dec 31, 2024.","Company plans to discuss with FDA to remove partial clinical hold and design registrational trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175624,"accession_number":"0001645666-25-000004","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kezar presents zetomipzomib safety update from PALIZADE Phase 2b lupus nephritis trial","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["KOL event hosted by William Blair covering zetomipzomib in autoimmune hepatitis and lupus nephritis.","Safety update from PALIZADE Phase 2b trial (active lupus nephritis) disclosed at event; no specific data provided.","No financial results, guidance changes, or regulatory decisions announced.","Company undertakes no obligation to update the presentation materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175623,"accession_number":"0001645666-25-000001","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Kezar Life Sciences reports preliminary cash of $132.2M as of Dec 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, and marketable securities at $132.2M as of December 31, 2024.","Shares outstanding of 7.3 million as of December 31, 2024.","Estimates are unaudited, subject to year-end closing adjustments; not a comprehensive financial statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192583,"accession_number":"0000950170-24-132818","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Kezar Life Sciences amends Rights Agreement with technical board administration changes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment No. 1 to Rights Agreement dated December 3, 2024 with Computershare Trust Company.","Makes technical amendments regarding board's administration and determination rights under the agreement.","Rights Agreement otherwise remains unmodified and in full force and effect.","Original Rights Agreement was dated October 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192582,"accession_number":"0000950170-24-127038","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Kezar Life Sciences regains Nasdaq compliance as stock price holds above $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff letter on Nov 13, 2024 confirming regained compliance.","Closing bid price was $1.00 or greater for 10 consecutive business days through Nov 13.","Now compliant with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement.","Resolves prior deficiency; no further action required from the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192581,"accession_number":"0000950170-24-125351","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Life Sciences reports Q3 loss $20.3M; halts PALIZADE LN trial over fatal SAEs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.3M ($2.78/share) vs $23.1M ($3.18) in Q3 2023; cash, equivalents and marketable securities $148.4M (Dec 31: $201.4M).","Terminated PALIZADE Phase 2b lupus nephritis trial after 4 fatal serious adverse events; full clinical hold by FDA.","PORTOLA autoimmune hepatitis trial: topline data expected H1 2025; IDMC recommended continue; FDA partial hold on open-label extension.","Completed 1-for-10 reverse stock split on Oct 29, 2024 to regain $1.00 minimum bid compliance on Nasdaq.","R&D expenses decreased to $16.2M from $23.7M; G&A to $5.7M from $8.8M due to strategic restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192580,"accession_number":"0000950170-24-117723","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Kezar Life Sciences announces 1-for-10 reverse stock split effective Oct 29, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1:10 ratio; shares reduce from 72,962,220 to 7,296,222.","Effective 5:00 p.m. ET Oct 29; trading on split-adjusted basis starts Oct 30.","Split aims to regain Nasdaq minimum bid price compliance of $1.00 per share.","No fractional shares; fractional holders receive rounding up to whole share.","No change to authorized shares, par value, or trading symbol KZR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192579,"accession_number":"0001193125-24-238562","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["1.01","2.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Kezar ends lupus trial after fatal SAEs, adopts poison pill to block $1.10 bid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued PALIZADE Phase 2b in lupus nephritis after 4 Grade 5 SAEs (1 placebo); 84 patients enrolled.","PORTOLA Phase 2a in autoimmune hepatitis continues; topline data due H1 2025.","Board rejected Concentra's $1.10/share bid; adopted rights plan (10%/15% threshold, expires Oct 17, 2025).","Preliminary cash ~$148M as of Sep 30, 2024; company says cash runway extended.","Concentra accumulated 9.9% of KZR; grandfathered but cannot increase without triggering rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192578,"accession_number":"0000950170-24-113963","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kezar receives unsolicited $1.10/share acquisition proposal from Concentra Biosciences","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Concentra offers $1.10 per share plus a contingent value right for 80% of net proceeds from out-licensing or disposition of Kezar's programs.","Tang Capital Management, which beneficially owns ~9.9% of Kezar, is Concentra's controlling stockholder.","Kezar's Board will evaluate the non-binding proposal to determine the best course for stockholders; no immediate action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192577,"accession_number":"0000950170-24-112969","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clinical hold on Kezar's zetomipzomib IND for lupus nephritis after 4 fatal SAEs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clinical hold on zetomipzomib IND for lupus nephritis after Kezar voluntarily suspended PALIZADE trial enrollment.","Four Grade 5 (fatal) SAEs in PALIZADE trial (Philippines and Argentina) led to IDMC recommendation for suspension.","Phase 2a PORTOLA trial for autoimmune hepatitis remains active; no Grade 4 or 5 SAEs observed.","FDA to provide official clinical hold letter within 30 days; company investigating fatal cases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209045,"accession_number":"0000950170-24-110177","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kezar halts lupus trial after 4 deaths; IDMC recommends stop","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary cessation of enrollment and dosing in PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis.","IDMC recommendation after review of 4 Grade 5 (fatal) serious adverse events in Philippines and Argentina.","Three fatalities showed common symptom pattern and proximity to dosing; additional non-fatal SAEs with similar pattern.","Kezar remains blinded to treatment arms; no prior deaths or serious opportunistic infections in earlier trials.","PORTOLA trial in autoimmune hepatitis continues enrollment; no Grade 4 or 5 SAEs observed there to date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209044,"accession_number":"0000950170-24-096165","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Life Sciences reports Q2 2024 net loss $21.5M; stops KZR-261 Phase 1, revises PORTOLA data to H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.5M ($0.30 per share) vs $24.3M ($0.34) in Q2 2023; cash $164.2M (down from $201.4M Dec 2023).","Enrollment completed in PORTOLA Phase 2a for autoimmune hepatitis; topline data expected first half 2025 (revised from prior guidance).","Enrollment stopped in KZR-261 Phase 1 for refractory solid tumors; no objective responses observed, resources redirected to zetomipzomib.","PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.","R&D expenses down $4.7M to $16.3M vs $21.0M; restructuring charge $1.5M related to office space impairment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226892,"accession_number":"0000950170-24-076234","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kezar Life Sciences stockholders reject Say-on-Pay, approve reverse split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-Pay advisory vote failed: 27.2M against vs 19.8M for.","Reverse stock split authorized (ratio 1:2 to 1:20) at Board's discretion.","Directors Christopher Kirk and John Fowler elected with >33M votes each.","KPMG ratified as independent auditor for FY2024 with overwhelming support.","Company will hold annual Say-on-Pay votes until 2030 after advisory vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226891,"accession_number":"0000950170-24-068730","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Kezar Life Sciences gets 180-day extension to regain Nasdaq minimum bid; transfers to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 31, 2024 approving transfer to Nasdaq Capital Market and additional 180-day compliance period until Nov 25, 2024.","Common stock had not regained compliance with $1.00 minimum bid price since initial notice in December 2023.","Transfer to Nasdaq Capital Market effective June 4, 2024; ticker remains KZR.","Company will monitor bid price and may consider a reverse stock split to meet the requirement.","Failure to comply by Nov 25, 2024 could result in delisting; appeal rights exist but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226890,"accession_number":"0000950170-24-056871","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Life Sciences Q1 net loss $21.7M; cash $179.8M; clinical trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities totaled $179.8M as of March 31, 2024, down from $201.4M at Dec 31, 2023.","Net loss $21.7M ($0.30 per share) vs $22.2M ($0.31) in Q1 2023; R&D expenses $17.2M, G&A $6.5M.","PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.","PORTOLA Phase 2a for autoimmune hepatitis enrolling; topline data expected mid-2025.","KZR-261 dose expansion in melanoma enrolling; initial study data expected by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245840,"accession_number":"0000950170-24-031448","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Life Sciences reports 2023 net loss of $101.9M; cash at $201.4M; trial timelines reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities totaled $201.4M as of Dec 31, 2023, down from $276.6M year-end 2022.","Net loss for 2023 was $101.9M ($1.40 per share) vs $68.2M ($1.01 per share) in 2022.","R&D expenses for 2023 increased 68% to $85.7M, driven by PALIZADE, PORTOLA trials and milestone payment to Onyx.","Restructuring and impairment charges of $6.2M in Q4 2023 from employee termination benefits and asset impairment.","PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) enrolling; topline data expected mid-2026 and mid-2025 respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245839,"accession_number":"0000950170-24-002728","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Kezar Life Sciences preliminarily estimates $201.4M cash, 72.8M shares as of Dec 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of approximately $201.4 million as of December 31, 2023.","Common stock outstanding estimated at 72.8 million shares as of December 31, 2023.","Estimates are unaudited and may change after completion of year-end closing and auditing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263299,"accession_number":"0000950170-23-067777","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Kezar receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter Dec 1, 2023; stock closed below $1.00 for 30 consecutive business days.","Company has 180 days, until May 29, 2024, to regain compliance.","Must close at $1.00+ for 10 consecutive business days to cure.","May qualify for additional 180-day period if transferred to Nasdaq Capital Market.","Company will monitor bid price and evaluate options, including reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263298,"accession_number":"0000950170-23-062918","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Q3 net loss $23.1M; appoints new CEO, restructures to extend cash runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.1M ($0.32/share) vs $17.8M loss in Q3 2022; revenue of $7.0M from Everest upfront.","Cash, equivalents, marketable securities $218.2M at Sep 30, down from $276.6M at Dec 31, 2022.","Co-founder Christopher Kirk appointed CEO Nov 7, replacing John Fowler who remains on board.","Strategic restructuring pauses drug discovery, extends cash runway into late 2026; focuses on zetomipzomib and KZR-261.","Collaboration with Everest Medicines for zetomipzomib in Greater China, South Korea, SE Asia; Everest joins PALIZADE trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":7000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263297,"accession_number":"0000950170-23-055985","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kezar Life Sciences enters separation agreement with former CMO Noreen Roth Henig","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Henig stepped down as CMO effective Oct 6, 2023; separation agreement signed Oct 23, 2023.","Cash severance: 12 months base salary plus 40% of target bonus, paid over 12 months.","Reimbursement of up to 12 months of COBRA premiums; vested stock option exercise extended to Dec 31, 2024.","Severance contingent on a general release of claims effective Oct 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263296,"accession_number":"0000950170-23-051526","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"Kezar Life Sciences cuts workforce 41%, appoints Christopher Kirk as CEO, extends cash runway to late 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~41%, pausing all research and drug discovery; severance charge of $2.9M-$3.2M expected in Q4 2023.","CEO John Fowler resigns Nov 7; co-founder Christopher Kirk appointed CEO with $600k salary, $75k bonus, 875k stock options.","CMO Noreen Roth Henig steps down Oct 6; Zung To assumes clinical operations oversight.","Cash runway extended to late 2026; PALIZADE Phase 2b LN data mid-2026. KZR-261 Phase 1 data 2024, PORTOLA AIH data mid-2025.","Exploring strategic partnering for protein secretion platform and preclinical programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280497,"accession_number":"0000950170-23-049044","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kezar licenses zetomipzomib to Everest for up to $132.5M in Greater China & SE Asia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kezar receives $7.0M upfront; eligible for up to $132.5M in development, regulatory & commercial milestones.","Everest gets exclusive rights to develop and commercialize zetomipzomib for non-oncology uses in Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines.","Parties will collaborate on PALIZADE Phase 2b lupus nephritis trial; Everest contributes local expertise and covers costs in licensed territories.","Tiered royalties from single-digit to low-teens on net sales; Kezar supplies drug with Everest option to manufacture after PALIZADE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280496,"accession_number":"0000950170-23-041949","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kezar Life Sciences delays KZR-261 dose expansion to 2024, still enrolling Cohort 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of KZR-261 in solid tumors enrolling Cohort 7 (40 mg/m2); no MTD reached yet.","Revised forecast pushes safety/dose escalation data report and dose expansion start to 2024.","Topline data from expansion portion to be reported when available.","Trial evaluates safety, PK/PD, and preliminary anti-tumor activity in locally advanced/metastatic disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280495,"accession_number":"0000950170-23-041305","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Life Sciences Q2 net loss $24.3M; cash $236.6M; clinical trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.3M ($0.34 per share) vs $16.2M ($0.25) in Q2 2022.","Cash equivalents and marketable securities $236.6M at June 30, 2023, down from $276.6M at Dec 31, 2022.","R&D expenses rose to $21.0M from $11.3M year-over-year, driven by zetomipzomib and KZR-261 programs.","PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) open for enrollment; KZR-261 dose escalation continues."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280494,"accession_number":"0000950170-23-034761","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kezar Life Sciences reprices executive stock options to $2.28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved repricing of 2018 Plan options to $2.28/share, the July 24 closing price.","CEO John Fowler: 2,655,000 options repriced from $3.29-$22.85; CFO Marc Belsky: 765,000 options.","CMO Noreen Roth Henig (980,000 options) and Strategic Advisor Christopher Kirk (832,500) included.","Repricing excludes options under the 2015 Plan and 2022 Inducement Plan; all other terms unchanged.","Purpose: retain key contributors and preserve cash without additional equity dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299089,"accession_number":"0000950170-23-028600","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Kezar Life Sciences increases authorized shares to 260M following stockholder vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares raised from 135M to 260M (250M common, 10M preferred) via certificate amendment effective June 14, 2023.","Stockholders approved the amendment with 65.3M votes for, 0.9M against, 0.1M abstentions.","Three Class II directors elected: Franklin Berger, Graham Cooper, Micki Klearman, M.D.; all terms until 2026.","KPMG LLP ratified as independent auditor for fiscal 2023 with 66.2M votes for, 5.2K against, 3.1K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299088,"accession_number":"0000950170-23-021203","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Life Sciences Q1 2023 net loss $22.2M; cash $257.7M; trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.2M ($0.31 per share) vs $16.0M ($0.26 per share) in Q1 2022.","Cash, cash equivalents and marketable securities $257.7M as of March 31, 2023, down from $276.6M at Dec 31, 2022.","R&D expenses increased to $18.3M from $10.9M, driven by advancing zetomipzomib and KZR-261 programs.","PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis on track to initiate in H1 2023.","KZR-261 dose escalation study enrolling Cohort 6; dose expansion expected H2 2023 with topline data mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299087,"accession_number":"0000950170-23-015303","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kezar Life Sciences President & CSO Kirk resigns, enters $41K/mo advisor deal","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Kirk resigned as President and CSO effective April 21, 2023, remains on board.","Advisor agreement runs April 22 to Dec 31, 2023 at $41,050/month plus COBRA premiums.","Kirk declines cash and equity compensation under Non-Employee Director Compensation Policy during term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319255,"accession_number":"0000950170-23-007861","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Life Sciences reports FY2022 net loss $68.2M; cash $276.6M; PALIZADE trial to start H1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities totaled $276.6M as of Dec 31, 2022, up from $208.4M in 2021.","Net loss for FY2022 was $68.2M ($1.01 per share) vs $54.6M ($1.04 per share) in 2021.","R&D expenses for FY2022 increased to $51.0M from $38.9M, driven by advancing zetomipzomib and KZR-261 programs.","PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis to initiate in H1 2023; PORTOLA Phase 2a in autoimmune hepatitis ongoing.","KZR-261 dose escalation currently enrolling Cohort 6; dose expansion study planned for H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319254,"accession_number":"0000950170-23-005140","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Kezar Life Sciences President & CSO Christopher Kirk resigns; internal promotions announced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Kirk, Ph.D. resigns as President and CSO effective April 21, 2023 for personal reasons; will remain on Board as strategic advisor.","Neel Anand, DPhil promoted to SVP, Research and Drug Discovery; Kieron Wesson, Ph.D. promoted to SVP, CMC and Supply Chain.","Both new SVPs report to CEO John Fowler as part of the company's succession plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319253,"accession_number":"0000950170-23-000395","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Kezar Life Sciences reports preliminary cash of $276.6M and 68.5M shares outstanding as of Dec 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of ~$276.6M as of Dec 31, 2022.","Approximately 68.5 million shares of common stock outstanding as of year-end 2022.","Estimates are unaudited and subject to change upon completion of year-end closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337462,"accession_number":"0000950170-22-024446","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Q3 net loss $17.8M; positive lupus nephritis data and FDA IND clearance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.8M ($0.25/share) vs $14.5M in Q3 2021; operating expenses rose to $18.9M.","Cash $290.4M at Sept 30, up from $208.4M at Dec 31, 2021, driven by ATM proceeds.","MISSION Phase 2 lupus nephritis: ORR 64.7% at week 25, 88.2% at week 37; CRR 35.3% then 41.2%.","FDA cleared IND for zetomipzomib in autoimmune hepatitis; PORTOLA Phase 2a trial to start.","Preclinical KZR-540, an oral PD-1 expression blocker, presented at SITC on Nov 11."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337461,"accession_number":"0000950170-22-021739","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kezar Life Sciences reports positive MISSION Phase 2 results: 64.7% ORR at Week 25, increases to 94.1% in follow-up","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR (≥50% proteinuria reduction) in 11/17 patients (64.7%) at Week 25; increased to 94.1% at Week 29 and 88.2% at Week 37.","CRR (UPCR ≤0.5) achieved in 35.3% at end of treatment, rising to 41.2% during safety follow-up (Week 29 & 37).","Mean background corticosteroid use reduced by 53%; by Week 13, 82.4% on ≤10 mg/day steroids.","SLEDAI-2K reduced from 11.3 baseline to 6.5 at EOT; Physician Global Assessment from 57.2 to 23.9.","Zetomipzomib well-tolerated; no Grade 3 infections; early terminations in 4/21 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354831,"accession_number":"0000950170-22-016846","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kezar Q2 2022: Net loss $16.2M, cash $306.8M; positive Phase 2 lupus nephritis data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive MISSION Phase 2 topline: 64.7% ORR, 35.2% CRR in lupus nephritis patients.","Cash, cash equivalents and marketable securities totaled $306.8M as of June 30, 2022 (up from $208.4M year-end 2021).","Net loss for Q2 2022 was $16.2M ($0.25 per share) vs $13.0M in Q2 2021.","Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer in July 2022.","R&D expenses $11.3M (+$2.0M YoY); G&A $5.0M (+$1.3M YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354830,"accession_number":"0000950170-22-012595","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Kezar Life Sciences estimates $307M cash, cash equivalents and marketable securities as of June 30, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities balance of approximately $307 million as of June 30, 2022.","Estimate is unaudited and subject to quarter-end closing adjustments.","No other financial results for Q2 2022 provided; comprehensive statement not yet available.","Company emphasizes this is a preliminary estimate and not a complete financial report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372852,"accession_number":"0000950170-22-012194","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kezar Phase 2 MISSION trial: 64.7% overall renal response rate in lupus nephritis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["11 of 17 patients (64.7%) achieved overall renal response (≥50% reduction in UPCR) at 6 months.","6 of 17 patients (35.2%) achieved complete renal response (UPCR ≤0.5, eGFR stable, steroids ≤10 mg/day).","Zetomipzomib well tolerated; most AEs mild-to-moderate; no Grade 3 infections reported.","Mean daily prednisone reduced from 19.2 mg at baseline to 9.1 mg at end of treatment.","Company plans continued development for lupus nephritis and evaluation for systemic lupus erythematosus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372851,"accession_number":"0000950170-22-011752","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kezar Life Sciences reports 2022 annual meeting voting results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Elizabeth Garner, Michael Kauffman, and Courtney Wallace as Class I directors until 2025.","Garner received 32,387,898 votes for; Kauffman 29,866,607; Wallace 45,460,015.","Ratification of KPMG as independent auditor for FY2022 passed with 56,166,095 for, 12,016 against, 1,946 abstain.","No other proposals were voted on; all nominees and auditor ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372850,"accession_number":"0000950170-22-009882","cik":1645666,"company_name":"Kezar Life Sciences, Inc.","ticker":"KZR","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chairman Jean-Pierre Sommadossi resigns; Graham Cooper appointed Chairman of Kezar Life Sciences","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jean-Pierre Sommadossi resigned as Chairman and from the Board, effective May 11, 2022, no disagreement with management.","Board appointed current director Graham Cooper as Chairman on May 12, 2022.","Cooper received a one-time option to purchase 26,000 shares, vesting monthly over three years contingent on board service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-13T23:59:59+00:00|372850"}